Proove Biosciences Launches World’s First Test to Predict Side Effect Risk to Commonly Prescribed NSAID Medications

Share Article

The new Proove NSAID Risk profile evaluates genetic factors to predict a patient’s side effect risk to nonsteroidal, anti-inflammatory medications before prescribing.

Unfortunately in most cases, doctors and patients do not realize there is a problem until it's too late...

Proove Biosciences, a commercial and research leader in Personalized Medicine, is excited to announce the launch of Proove NSAID Risk™ profile. This profile focuses on genetic variations involved with the innate immunity and inflammation associated with NSAID side effects to predict good versus poor responders and provide dosing information for commonly prescribed nonsteroidal, anti-inflammatory medications, namely aspirin (brand name Bayer, Excedrin), ibuprofen (brand name Advil, Motrin), and naproxen (brand name Aleve). Proove’s NSAID Risk profile will assist physicians with properly prescribing NSAIDs at optimal doses for each patient’s individual needs, shorter duration of therapy and lower costs.

NSAIDs are a group of medications used to temporarily relieve pain and inflammation. They work by inhibiting the cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) enzymes, which are involved in pro-inflammatory pathways that produce prostaglandins, prostacyclins, and thromboxanes. However, a number of patients have experienced adverse outcomes, including gastrointestinal bleeding, cardiovascular events, and gastric or rectal cancer with NSAID use. Numerous investigations have demonstrated that this phenomenon may be, in part, attributed to the broad variability in individual response profiles and to genetic polymorphisms in candidate genes involved in immunological and inflammatory signaling pathways. Using these polymorphisms to identify patients at risk of adverse events will play an important role in modulating NSAID risk factors.

“It has been estimated, that over 16,500 deaths each year are related to NSAID use – more than AIDS. Some of these incidents, for example include lower gastrointestinal complications from these NSAID’s. Unfortunately in most cases, doctors and patients do not realize there is a problem until it is too late,” stated Proove Founder and CEO Brian Meshkin. “With the Proove NSAID Risk profile, we are able to predict these issues to hopefully avoid these occurrences happening in the future. With a simple cheek swab, this profile provides the physicians and patients with insights into side effects, resulting in better clinical and economic outcomes.”

About Proove Biosciences
Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could’ve ever prescribed medications without knowing how a patient would respond. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit or call toll free 855-PROOVE-BIO (855-776-6832).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicole McMillan
Proove Biosciences
+1 855-776-6832 Ext: 1546
Email >
Follow >
Proove Biosciences, Inc.
since: 02/2012
Like >
Proove Biosciences, Inc.

Visit website